News: 2012
Merus Appoints Setareh van Driel Shamsili as Chief Medical Officer
December 14, 2012
Utrecht, The Netherlands, December 11, 2012 - Merus B.V., a biopharmaceutical company focused on innovative human antibody therapeutics, today announced the appointment of Setareh van Driel Shamsili, MD, Ph....
Read more
SomantiX and VU University Medical Center Amsterdam receive EuroTransBio (ETB) Grant for Tumor Vessel Targeting program
November 08, 2012
Amsterdam, The Netherlands, November 7th 2011 - The grant of EUR 1.5 million is awarded to a multidisciplinary consortium including SomantiX and the VU University Medical Center Amsterdam by the European col...
Read more
InteRNA Technologies receives notice of allowance for miRNA sequences of its lead pre-clinical product
October 15, 2012
Patent covers the precursor and mature sequences of miRNA-3157, the Company's lead product in its B-Raf/melanoma program
Nijmegen/Utrecht, the Netherlands - October 15, 2012 - InteRNA Technologies B.V., a d...
Read more
Merus announces the full validation of its MeMo(R) transgenic mouse for common light chain human antibodies
October 09, 2012
UTRECHT - The Netherlands - October 8, 2012 - Merus B.V., a biopharmaceutical company focused on innovative human antibody therapeutics, announced today the full validation of its transgenic MeMo® mouse for...
Read more
ORCA Therapeutics strengthens its Patent Portfolio
September 06, 2012
Amsterdam, The Netherlands - September 6th, 2012 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announced today that it has expanded its patent port...
Read more
Merus receives EP patent covering the expression of defined antibody combinations
June 21, 2012
Utrecht, The Netherlands, June 20, 2012 - Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that it has been granted the first European patent cove...
Read more
Merus announces appointment of Jason Avery as Chief Business Officer
June 18, 2012
Utrecht, The Netherlands, June 15, 2012 - Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that Jason Avery has been appointed as Chief Business O...
Read more
